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A B S T R A C T
Coronary artery disease remains an important cause of morbidity and mortality world-wide. Coronary Computed Tomography Angiography (CCTA) has excellent
diagnostic accuracy and the identification and stratification of coronary artery disease is associated with improved prognosis in multiple studies. Recent randomized
controlled trials have shown that in patients with stable coronary artery disease, CCTA is associated with improved diagnosis, changes in investigations, changes in
medical treatment and appropriate selection for revascularization. Importantly this diagnostic approach reduces the long-term risk of fatal and non-fatal myocardial
infarction. The identification of adverse plaques on CCTA is known to be associated with an increased risk of acute coronary syndrome, but does not appear to be
predictive of long-term outcomes independent of coronary artery calcium burden. Future research will involve the assessment of outcomes after CCTA in patients
with acute chest pain and asymptomatic patients. In addition, more advanced quantification of plaque subtypes, vascular inflammation and coronary flow dynamics
may identify further patients at increased risk.
1. Introduction
Cardiovascular disease remains an important cause of morbidity and
mortality world-wide, responsible for 17.9 million deaths per year.1
Both the presence and extent of coronary artery disease identified on
coronary computed tomography angiography (CCTA) is associated with
an adverse prognosis in multiple single center studies and several large
multicenter registries. Recent research has shown that management
guided by CCTA is associated with improved outcomes for patients with
suspected coronary artery disease. The potential mechanisms for the
improvement in outcomes in patients undergoing CCTA include more
accurate diagnosis, appropriate use of medical therapy and appropriate
selection for revascularization. In addition to the identification of cor-
onary artery stenoses, CCTA can also identify the overall burden of
atherosclerotic plaque and plaque characteristics, which may be asso-
ciated with increased risk.
2. Detection and prognosis
CCTA has an excellent diagnostic accuracy, both in terms of the
ability to identify the presence of coronary artery plaque and the ability
to identify obstructive coronary artery stenoses.2 The high negative
predictive value means that CCTA can exclude the presence of coronary
artery disease and help avoid any further unnecessary investigations or
treatments. Conversely, CCTA can also risk stratify patients with cor-
onary artery disease, including the appropriate selection of those who
may benefit from revascularization (see Figs. 1 and 2).3
On the background of excellent diagnostic accuracy, several single
and multicenter registry studies have demonstrated that a normal CCTA
is associated with an excellent prognosis.4–6 In contrast, the presence
and magnitude of both non-obstructive and obstructive coronary artery
disease is associated with subsequent prognosis.6–9 This is true for both
symptomatic and asymptomatic patients with a wide range of cardio-
vascular risk factors. The identification and quantification of coronary
artery calcification (CAC), a surrogate marker of atherosclerosis, is also
associated with a poor prognosis in a wide range of patient populations.
Unlike CAC scoring, CCTA can identify plaque subtypes including both
calcified and non-calcified plaque, and can identify the presence and
severity of coronary artery stenoses. Several studies have shown that
CCTA is additive to CAC in the assessment of prognosis.10
CCTA has excellent diagnostic accuracy for the detection of cor-
onary artery disease and its ability to predict subsequent events was an
important first stage in the adoption of this technology. However, over
the past 5 years, several randomized controlled trials have addressed
the important question of whether management based on CCTA can
improve outcomes. These randomized controlled trials have set a
benchmark for further research into diagnostic strategies for patients
with suspected coronary artery disease.
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Fig. 1. Clinical Vignette 1. A 65-year-old male presented to the rapid access chest pain clinic with symptoms of typical angina. He was a current smoker with a past
medical history of gout. An exercise tolerance test was stopped early due to knee pain, but demonstrated no other abnormalities. His coronary artery calcium score
was 283 Agatston units. He underwent a CCTA which showed moderate non-obstructive disease (CAD-RADS 3) He had mild calcified plaque in the left anterior
descending (LAD) and right coronary artery (RCA), < 50% stenosis. He had moderate non-calcified plaque with positive remodelling in the proximal and distal left
circumflex artery (LCX), 50–70% stenosis. He presented 1 years later with an episode of acute chest pain on the background of 2 weeks of worsening chest pain.
Electrocardiogram (ECG) on admission showed ST depression in the inferior leads. High sensitivity troponin I was elevated at 2060 ng/L. He was diagnosed with a
non ST elevation myocardial infarction (NSTEMI). Invasive coronary angiography showed an occluded mid LCX (yellow arrows). There was also mild disease in the
LAD and moderate disease in the small RCA. A bare metal stent was inserted into the LCX and he was asymptomatic on subsequent follow-up. . (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2. Clinical Vignette 2. A 67-year-old female presented to the rapid access chest pain clinic with atypical chest pain. She had hypertension but no other
cardiovascular risk factors. Her estimated 10-year risk of cardiovascular disease was 14% (ASSIGN score). An exercise tolerance test was normal. Her coronary artery
calcium score was 62 Agatston units. CCTA identified single vessel obstructive coronary artery disease (CAD-RADS 4A). There was severe mixed plaque in the
proximal and mid LAD,> 70% stenosis. The plaque in the proximal LAD demonstrated positive remodelling and spotty calcification. There was also mild disease in
the mid RCA and proximal LCX,< 50% stenosis. 4 years later she presented to the emergency department with acute chest pain. ECG showed ST depression in the
inferior leads. High sensitivity troponin I was elevated at 387 ng/L. Invasive coronary angiogram showed an occluded LAD (yellow arrows) and mild disease in the
LCX and RCA. The LAD was treated with a drug eluting stent. She had no further hospital admissions in the subsequent 3 years. . (For interpretation of the references
to colour in this figure legend, the reader is referred to the Web version of this article.)
M.C. Williams, et al. Journal of Cardiovascular Computed Tomography xxx (xxxx) xxx–xxx
2
3. Improved outcomes in patients with stable chest pain
Chest pain represents an important, and frequent, reason for con-
sultation in both primary and secondary care.11,12 The many potential
causes of chest pain mean that accurate diagnosis is an essential aspect
of clinical care. Anginal chest pain due to coronary artery disease is an
important diagnosis of both inclusion and exclusion for subsequent
patient management. Recently two large multi-center randomized
controlled trials and two smaller randomized trials, have addressed the
question of prognostic outcomes after CCTA (Table 1). These include
the Scottish Computed Tomography of the HEART trial (SCOT-
HEART)13–15 and the Prospective Multicenter Imaging Study for Eva-
luation of Chest Pain (PROMISE) trial.16,17
3.1. Study design of the multi-center randomized controlled trials
SCOT-HEART is a large multi-center trial based in the UK which
assessed the use of CCTA in stable patients attending cardiology out-
patient clinics.13 It recruited 4146 patients between 18 and 75 years,
without excluding patients based on the presence of atrial fibrillation,
body mass index or coronary artery calcium score. Patients were ran-
domized to standard care or standard care plus computed tomography
(CT). The primary outcome was the diagnosis of angina due to coronary
artery disease at 6 weeks.14 Patients were followed-up for the primary
clinical outcome of coronary heart disease death or non-fatal myo-
cardial infarction at 5 years.15
PROMISE is a large multi-center trial based in the US which con-
ducted a head-to-head comparison of CCTA with functional stress
testing in just over 10,000 patients with suspected coronary artery
disease.16 The functional testing arm included exercise electro-
cardiography (10%), exercise or pharmacologic nuclear stress testing
(70%), and stress echocardiography (20%). The primary outcome was a
composite of death, non-fatal myocardial infarction, hospitalization for
unstable angina, or major procedural complication (including renal
failure and anaphylaxis), and patients were follow-up for 2 years.17
3.2. Outcomes in the randomized controlled trials
The SCOT-HEART trial showed an improvement in outcomes in the
CCTA group with a reduction in death from coronary heart disease or
non-fatal myocardial infarction at both 2 (hazard ratio (HR) 0.62, 95%
CI 0.38 to 1.01, p= 0.0527) and 5 years (HR 0.59, 95% confidence
interval (CI), 0.41 to 0.84, p=0.004).12,13 This was largely driven by
reduction in the risk of non-fatal myocardial infarction. Thus, the SCOT-
HEART study demonstrated for the first time that management based
on the results of a non-invasive diagnostic test can improve coronary
artery disease outcomes in a randomized controlled trial.
The PROMISE trial showed no differences in the primary composite
endpoint of death, non-fatal myocardial infarction, hospitalization for
unstable angina and major procedural complication between the CCTA
and functional care groups (HR 1.04, 95% CI 0.83 to 1.29, p= 0.75) at
2 years.17 A statistical nuance is that these results failed to meet both
superiority and non-inferiority criteria, leaving the impact of this study
debated. However, consistent with the SCOT-HEART trial, there was a
lower rate of death or non-fatal myocardial infarction in the CCTA
group (HR 0.66, 95% CI 0.44 to 1.00, p=0.049) at 12 months where
they had 93% complete follow-up data.17 PROMISE suggests that
management based on both strategies is safe and suitable for the as-
sessment of patients with suspected coronary artery disease.
Two smaller randomized controlled trials have assessed outcomes in
patients with stable chest pain. The CAPP (Cardiac CT for the
Assessment of Pain and Plaque) trial was a single center randomized
controlled trial comparing CCTA and exercise ECG which recruited 448
patients.18 It found no difference in major adverse cardiac events be-
tween groups, but this trial was underpowered for this outcome. A
study by Min et al. randomized patients to CCTA or myocardial per-
fusion single-photon emission computed tomography and recruited 180
patients.19 At 55 days, no patient had a myocardial infarction or died,
although this study was again underpowered. A meta-analysis has as-
sessed the combined outcomes of these studies, including the 2 but not
5-year SCOTH-HEART results.20 It found that patients undergoing
CCTA had a significant reduction in the annual rate of myocardial in-
farction (rate ratio 0.69, 95% CI 0.49 to 0.98, p= 0.038) but no dif-
ference in all-cause mortality (rate ratio 0.96, 95% CI 0.72 to 1.28,
p=0.78).20
4. Mechanisms for improved outcomes in patients undergoing
CCTA
There are a variety of mechanisms by which patients undergoing
CCTA may benefit from subsequent improved outcomes. This includes
more accurate diagnosis, optimization of medical therapy, appropriate
use of subsequent investigations including invasive coronary angio-
graphy and appropriate selection for revascularization.
4.1. CCTA improving diagnosis
For over 20 years, risk stratification models have been central to the
diagnosis of patients with chest pain.21 However these models have
several limitations. First, the data used to create them was obtained
prior to the development of modern management strategies. Second,
they include patients with a limited range of age, sex and ethnicity.
Third, they led to a limited stratification of patients, with many in the
pre-test probability range of 10–90%.22 Thus the diagnostic ability of
risk prediction models is limited.
CCTA provides an accurate answer to the question of whether or not
the patient has coronary artery disease and can also provide informa-
tion as to the likelihood of whether the patient's symptoms are likely to
be secondary to coronary artery disease. In the SCOT-HEART trial,
CCTA led to a change in diagnosis in 23% of patients, compared to 1%
Table 1
Randomized controlled trials of CCTA in patients with stable chest pain.13–19.
PROMISE SCOT-HEART CAPP Min et al.
Number of patients 10,003 4146 448 180
CCTA vs Functional testing Standard care Stress ECG MPI
Age (years) 61 57 59 56, 59
Female (%) 53 44 45 44
Pre-test probability (%) 53 47 45, 48
Symptoms Typical angina 12 35 34 32
Atypical angina 78 24 8 23
Non-anginal chest pain 11 41 67 27
Follow-up (months) 25 21, 58 12 2
PROMISE, Prospective Multicenter Imaging Study for Evaluation of Chest Pain; SCOT-HEART, Scottish Computed Tomography of the HEART; CAPP, Cardiac CT for
the Assessment of Pain and Plaque; ECG, electrocardiogram; MIP, myocardial perfusion imaging; CCTA, computed tomography coronary angiography.
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in the standard care arm (p < 0.001).14 Improvements in the accuracy
of the diagnosis are important in providing the optimal clinical care. In
addition to diagnostic accuracy, CCTA can also improve the certainty of
a diagnosis. In SCOT-HEART, CCTA improved the certainty of the di-
agnosis of coronary artery disease (relative risk (RR) 2.56, 95% CI 2.33
to 02.79, p < 0.0001) and angina due to coronary artery disease (RR
1.79, 95% CI 1.62 to 1.96, p < 0.001). The certainty of a diagnosis has
important implications for the subsequent actions of both physicians
and patients.23 It should be noted that exclusion of CAD, whether in its
entirety, or as a likely cause of symptoms, is as important as the con-
firmation of significant disease. This also informs the most appropriate
management strategy, which may not include pharmacological or
physical intervention.
4.2. CCTA and optimization of medical management
The use of CCTA can lead to changes in the medical management of
patients. This includes the starting of new medications in patients who
have coronary artery disease, or the stopping of unnecessary medica-
tions in patients who have been shown to have normal coronary ar-
teries.
In the SCOT-HEART study, there was a change in medical treat-
ments in 27% of patients in the CCTA group and 5% in the standard
care group.14 This included changes in recommendations for both
preventative (18% vs 4%, p < 0.001) and anti-anginal treatments (9%
vs 1%, p < 0.001).14 A subsequent Danish registry study of 86,705
patients who underwent functional testing or CCTA also showed that
the use of CCTA was associated with changes in medical manage-
ment.24 They found that there was increased use of preventative med-
ications after CCTA compared to functional testing, including statins
(26% vs 9%, p < 0.001) and aspirin (13% vs 9%, p < 0.001).24 Sev-
eral other smaller studies have shown that CCTA leads to the in-
tensification of preventative medical therapies19,25,26 and subsequent
improvements in cholesterol measurements.27
Another important factor that CCTA can influence is the continua-
tion of long-term preventative medications. A variety of patient and
clinician factors can impact compliance with medication re-
commendations, including demographic, clinical, socio-economic, and
belief-related factors.28,29 The identification of CAC is associated with
increased adherence to statin therapy, and patients with higher CAC
score are more likely to adhere to statin therapy.30–32 In the SCOT-
HEART trial, there was increased use of preventative therapy in patients
in the CCTA group throughout follow-up, particularly in those with
coronary artery disease.
Therefore, it can be surmised that changes in medical management
after CCTA are likely to be important factors in the improvement of
outcomes after CCTA through both the individualization of medical
treatment recommendations and improvement in subsequent ad-
herence.
4.3. CCTA and appropriate use of downstream investigations
Initial criticism of CCTA was that it would merely increase the
number of subsequent diagnostic tests that are performed. However,
this has not been confirmed in long-term follow-up studies. The iden-
tification of coronary artery disease per se does not necessitate invasive
imaging. Indeed, the majority of patients who undergo CCTA do not
require any further imaging investigations. Invasive coronary angio-
graphy should be reserved for patients who are likely to require re-
vascularization. In this respect, CCTA can be used as a “gate-keeper” for
subsequent invasive investigation.
CCTA led to changes in investigations in 15% of patients, compared
to 1% in the standard care group (p < 0.0001).14 This included the
cancellation of investigations, particularly additional functional ima-
ging, and the organisation of new investigations, primarily invasive
coronary angiography. Although there was an early increase in the use
of invasive coronary angiography in both the PROMISE and SCOT-
HEART trials, the overall rates of invasive coronary angiography were
similar in the CCTA group and the standard care group by 5 years of
follow-up (HR 1.00, 95% CI 0.88, 1.13).15 This suggests the more ap-
propriate targeted use of invasive coronary angiography after CCTA
that reduced the need for subsequent downstream invasive angio-
graphy. The study by Min et al. also identified similar rates of invasive
coronary angiography after CCTA and functional testing.19 A meta-
analysis of CCTA studies showed that there was a trend towards more
invasive coronary angiography after CCTA (OR 1.33, 95% CI 0.95 to
1.84, p= 0.09),20 but this did not include studies with long-term
follow-up.
The rates of normal coronary arteries identified on diagnostic in-
vasive coronary angiography varies depending on the center, indication
or population, but has been quoted as being over 50%.33 Due to the
potential for rare but serious complications, its invasive nature, and the
cost, it is important to ensure the appropriate use of invasive coronary
angiography. Indeed, in the era of non-invasive imaging, finding
normal coronary arteries on invasive coronary angiography should be
an uncommon event. The PROMISE trial showed that there were fewer
invasive coronary angiograms showing normal coronary arteries in the
CCTA group compared to the functional testing group (3.4% vs 4.3%,
p=0.02).17 Similarly in the SCOT-HEART trial, CCTA was associated
with a decreased rate of normal coronary arteries (HR 0.39, 95% CI
0.23 to 0.68, p < 0.001).34 Other studies have also shown a reduction
in the frequency of normal coronary arteries at invasive coronary an-
giography after CCTA, confirming that CCTA can be used as a gate-
keeper for the use of invasive coronary angiography.3
4.4. CCTA and appropriate use of revascularization
CCTA can assist the appropriate selection of patients who may
benefit from revascularization. In the PROMISE trial, CCTA was asso-
ciated with an increase in the number of patients undergoing re-
vascularization (6.2% vs 3.2%, p < 0.001).17 A meta-analysis of ran-
domized controlled trials, which included the 2 but not 5-year follow-
up of the SCOT-HEART trial, found that there was a small increase in
revascularization after CCTA compared to usual care (7.9% vs 5.1%,
p < 0.001). The Danish registry study also showed an increase in in-
vasive coronary angiography and revascularization in the CCTA group
after 120 days of follow-up.24 In the first year of follow-up in the SCOT-
HEART trial, there was an increase in the use of revascularization in the
CCTA group (HR 1.21, 95% CI 1.01 to 1.46, p= 0.042). However, at 5
years, there was no difference in the rate of revascularization in the
CCTA or standard care groups (HR 1.07, 95% CI 0.91 to 1.27), because
beyond one year, there were higher rates of coronary revascularization
in the standard care group (HR 0.59, 95% CI 0.38 to 0.90, p=0.015).
This suggests that the CCTA can guide the early selection of appropriate
patients for both invasive coronary angiography and revascularization.
It also suggests that early and more targeted treatment in the CTCA
group prevented downstream longer-term disease progression, whereas
there was declaration of unrecognized disease in the standard care
group requiring further investigation and intervention.
5. CCTA and outcomes in patients with acute chest pain
Previous research into the use of CCTA in the Emergency
Department has primarily focused on improving the time-to-diagnosis.
Several randomized controlled trials have been performed in patients
with a low to intermediate pre-test probability (Table 2). These have
established that the presence of normal coronary arteries in patients
presenting with acute chest pain is associated with a good prognosis
and low risk of subsequent cardiac events. They have also shown that
CCTA is associated with reduced time to-diagnosis, reduced length of
hospital stay and reduced cost.35,36 However, a meta-analysis of the
randomized controlled trials in patients with acute chest pain found
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that there was no difference in the outcomes of all-cause mortality,
myocardial infarction or major adverse cardiac events between the
CCTA and standard care groups.37
Most of the previous studies of CCTA in the emergency department
occurred prior to the adoption of high sensitivity troponin. One small
trial, BEACON (Better Evaluation of Acute Chest Pain with Coronary
Computed Tomography Angiography), employed measurement of high
sensitivity troponin in all patients. This small study did not show any
difference in outcomes between the groups. Post-hoc analysis of high
sensitivity troponin in the ROMICAT II study identified a group of pa-
tients who could be discharged with good outcomes based on high
sensitivity troponin and risk factors alone.38 Further randomized con-
trolled trials are underway to assess the outcomes of patients under-
going CCTA in the Emergency Department including the RAPID-CTCA
(Rapid Assessment of Potential Ischaemic Heart Disease with CTCA;
NCT02284191) and TARGET-CTCA (Troponin in Acute chest pain to
Risk stratify and Guide EffecTive use of Computed Tomography Cor-
onary Angiography) trials.
6. CCTA and asymptomatic patients
In asymptomatic patients, the identification of CAC is associated
with clinical outcomes and a zero CAC score associated with an ex-
cellent prognosis.39,40 In addition, the identification and stratification
of coronary artery disease on CCTA predicts prognosis in registry stu-
dies of asymptomatic patients.41 The identification of coronary artery
disease in asymptomatic patients therefore moves us away from pri-
mary prevention, and towards a new form of secondary prevention of
coronary artery disease.
To date only one randomized controlled trial has assessed the use of
CCTA in asymptomatic patients. The FACTOR-64 trial (Screening For
Asymptomatic Obstructive Coronary Artery Disease Among High-Risk
Diabetic Patients Using CT Angiography, Following Core 64) recruited
900 patients with type 1 or 2 diabetes without a previous history or
symptoms of coronary artery disease.42 Patients were randomized to
either undergo CCTA or standard care. After 4 years, there was no
difference in the primary end point of all-cause mortality, non-fatal
myocardial infarction or unstable angina requiring hospitalization (HR
0.80, 95% CI 0.49 to 1.32, p= 0.38).42 However, this was a small trial,
and a large proportion of patients were already taking preventative
medication prior to CCTA. Therefore, the role of CCTA in the assess-
ment of asymptomatic patients remains uncertain. Other non-rando-
mized prospective studies support the utility of CCTA to identify cor-
onary artery disease in asymptomatic patients.43 Future research will
assess the role of CCTA in the broad population of patients with sus-
pected coronary artery disease, including the SCOT-HEART 2 trial.
7. Impact of adverse plaque characteristics on outcomes
Although the presence of coronary artery stenosis is associated with
subsequent events, most myocardial infarctions occur in segments with
non-obstructive rather than obstructive disease.44,45 Thus, the identi-
fication other plaque characteristics which are associated with prog-
nosis is important. An important advantage of CCTA is that in addition
to the identification of coronary artery stenosis, it can also assess plaque
characteristics. This can be in the form of visual assessment, or more
recently using software capable of semi-automated quantitative as-
sessment.
Simple assessment of plaque involves the identification of calcified,
non-calcified and mixed subtypes. The stratification of plaques with this
method has shown that non-calcified plaques in particular are asso-
ciated with acute coronary events.46 More detailed visual assessment
includes the identification of “adverse plaque features” including po-
sitive remodelling, low attenuation plaque, spotty calcification and the
“napkin-ring” sign. These features are associated with markers of his-
tological vulnerability47 and with prognosis in several studies.48–53 A
meta-analysis found that the risk of future ACS was increased in pa-
tients with high-risk plaque (OR 12.1, 95% CI 5.24 to 28.1,
p= 0.0001).54
In a study of 3158 patients followed up for 4 years, Motoyama et al.
found that the presence of positive remodelling or low attenuation
plaque was associated an increased likelihood ACS.50 Adverse plaques
are frequent on CCTA performed for both stable and acute chest pain
occurring in 15% of patients in the PROMISE trial, 35% in ROMICAT II
and 34% in SCOTHEART.54–56 In ROMICAT II, adverse plaque (positive
remodelling, low attenuation plaque, spotty calcification or “napkin-
ring”) were more frequent in patients with ACS (odds ratio 8.9, 95% CI
1.8 to 43.3, p= 0.006).55 In the PROMISE trial, adverse plaques (po-
sitive remodelling, low attenuation plaque, or “napkin-ring”) were as-
sociated with increased risk of death, myocardial infarction or hospi-
talization for unstable angina at 2 years (HR 2.73, 95% CI 1.89, 3.93).56
In the SCOT-HEART trial, adverse plaques (positive remodelling and/or
low attenuation plaque) were associated with an increased risk of
coronary heart disease death or myocardial infarction (HR 3.01, 95% CI
1.61 to 5.63, p=0.001), but this was not independent of CAC.57 This
suggest that the primary factor for long term prognosis is the overall
plaque burden rather than the presence of an adverse plaque on non-
invasive imaging. This is not surprising as the burden of coronary artery
disease measured as coronary artery calcium score, number of vessels
involved, or more complex scores are all predictive of outcomes. In
addition, the development of atherosclerotic plaque is a continuous
dynamic process. The fact that adverse plaques appear to be predictive
of ACS and early outcomes, but not of late outcomes, is consistent with
the theory of continuous plaque remodelling. An individual HRP may
undergo subsequent stabilisation or subclinical rupture, rather than
Table 2
Randomized controlled trials of CCTA improving outcomes in acute chest pain35,36,66,67.
ACRIN-PA BEACON CATCH CT-COMPARE CT-STAT Nabi
et al.
PERFECT PROSPECT ROMICAT-II
Number of patients 1368 490 576 562 699 598 395 400 1000
CCTA vs Stress ECG, stress
imaging
Stress ECG,
MPI
Stress ECG,
MPI
Stress ECG MPI MPI Stress echo.,
MPI
MPI Stress ECG, Stress echo.,
MPI
Age (mean years) 50 54 56 52 50 53 60 57 54
Female (%) 54 47 45 42 54 56 54 63 47
Follow-up (months) 12 1 19 12 6 7 12 12 1
ACRIN-PA, CT Angiography for Safe Discharge of Patients with Possible Acute Coronary Syndromes; BEACON, Better Evaluation of Acute Chest Pain with Coronary
Computed Tomography Angiography; CATCH, CArdiac cT in the treatment of acute CHest pain; CT-COMPARE, CT Coronary Angiography Compared to Exercise ECG;
CT-STAT, Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment; PERFECT, Prospective First Evaluation in
Chest Pain; PROSPECT, Prospective Randomized Outcome trial comparing radionuclide Stress myocardial Perfusion imaging and ECG-gated coronary CT angio-
graphy; ROMICAT-II, Rule Out MI/ischaemia Using Computer Assisted Tomography; ECG, electrocardiogram; MPI, myocardial perfusion imaging; echo., echo-
cardiography.
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present with ACS. Therefore, to predict long term events, the presence
of any plaque is more important than the type of plaque.
The retrospective nature of some studies to date, the high frequency
of adverse plaque, and the low frequency of clinical outcomes, means
that the relevance of the assessment of adverse plaque in clinical
practice is uncertain. In addition, the visual assessment of athero-
sclerotic plaque is time consuming and associated with observer
variability.58 Current research into the quantitative assessment of
atherosclerotic plaque aims to address these issues. Quantitative plaque
analysis has been used to assess plaque features associated with severe
stenoses,59 myocardial perfusion defects60 and abnormal computed
tomography fractional flow reserve (CT FFR).61 It has also been used to
assess differences in plaque types between diabetic and non-diabetic
patients,62 and assess plaque progression.62 The prognostic implication
of quantitative plaque assessment has been assessed in registry and case
control studies.63,64 In a study of 2748 patients, the quantification of
total, non-calcified and low-density plaque volumes and contrast den-
sity drop were predictive of cardiac death at 5 years of follow-up.64
Future research will improve the automation of these techniques but
there is a need to assess their impact in randomized studies of out-
comes. In addition, advanced computational techniques seek to identify
additional features of adverse plaques which are visible to the computer
rather than the human eye.65 This may be complementary to other
techniques which are under investigation such as CT assessment of
vascular inflammation or vascular flow dynamics.
8. Conclusion
CCTA can improve outcomes by identifying patients who may
benefit from medical therapy or revascularization. It can also identify
patients who do not have coronary artery disease and avoid un-
necessary investigation or life-long medication in these patients. Thus,
by improving the accuracy of diagnosis and facilitating appropriate
management, a diagnostic strategy including CCTA can improve out-
comes for patients with suspected coronary artery disease. There is
robust evidence for this in patients with stable chest pain and further
research is underway in patients with acute chest pain and asympto-
matic patients. The visual or quantitative assessment of plaque may
further improve outcomes for patients with coronary artery disease in
the future.
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